

# Inovio's CEO Kim Appointed to Aspen Institute's Health Innovators Fellowship

**Inovio Pharma {NASDAQ: INO}** proudly announced that their **CEO, DR Joseph Kim**, has been selected by the prestigious Aspen Institute to join its Health Innovators fellowship.

This honour has been bestowed in recognition of Dr. Kim's leadership in advancing a new type of medicine.

Immunotherapy Pioneer Will Work With Other Business and Medical Leaders to Create New Approaches to Improve Healthcare.

PLYMOUTH MEETING, Pa., July 13, 2015 **Inovio Pharmaceuticals, Inc. {NASDAQ: INO}** announced today that its **Chief Executive Officer, Dr. J. Joseph Kim**, has been selected by The Aspen Institute to join its Health Innovators Fellowship. Dr. Kim, who co-founded Inovio, will work with a group of 20 healthcare leaders challenged to generate new solutions to improve healthcare treatments, access and delivery. He also joins 2,000 other Aspen Fellows from 48 countries who comprise the Aspen Global Leadership Network.

Aspen chose Dr. Kim for his leadership in advancing a new type of medicine, DNA-based immunotherapies, that may prevent and treat a broad array of cancers and challenging infectious diseases, and for his entrepreneurial spirit guiding a two-person start-up through early-stage trials into a publically traded product development company, Inovio Pharmaceuticals Inc.

The Fellowship is designed for proven, highly successful

entrepreneurs and innovators in the health care field who have reached a point in their lives and careers when they are ready to use their skills and experiences to “paint on a broader canvas.” The Fellowship offers leaders a unique opportunity to reflect on how they can have an even greater positive impact on health care, and to connect with and learn from a diverse group of peers with whom they would not ordinarily interact.

“Our goal for the Health Innovators Fellowship is to bring together a diverse group of leaders to explore how they can harness their creativity, experience and energy to solve our most pressing health care challenges,” said Rima Cohen, managing director of the Health Innovators Fellowship. “As a pioneer in developing new immunotherapies and vaccines for cancer and infectious diseases, Dr. Kim’s perspective will be invaluable to our inaugural class.”

Dr. J. Joseph Kim, President and CEO, said, “I am honored to be selected by The Aspen Institute to join the inaugural class of Health Fellows. I look forward to working with these accomplished innovators as we develop ‘big ideas’ to improve health for everyone.”

### **The Aspen Global Leadership Network**

Health Innovators Fellows will join more than 2,000 other Fellows from 48 countries to become members of the Aspen Global Leadership Network (AGLN). The AGLN is composed of accomplished leaders who have participated in similar Aspen Institute leadership initiatives in the United States, Africa, Central America, China, India, and the Middle East – all designed to help accomplished leaders – mostly business

leaders – move from “*success to significance.*”

The Aspen Institute is an educational and policy studies organization based in Washington, DC. Its mission is to foster leadership based on enduring values and to provide a nonpartisan venue for dealing with critical issues. The Institute has campuses in Aspen, Colorado, and on the Wye River on Maryland’s Eastern Shore. It also maintains offices in New York City and has an international network of partners.

### **About Inovio Pharmaceuticals, Inc.**

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit – [www.inovio.com](http://www.inovio.com).

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events

or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other

significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended March 31, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

**CONTACT:**

Bernie Hertel, Inovio Pharmaceuticals,  
+1 858 410 3101

[bhertel@inovio.com](mailto:bhertel@inovio.com)